<DOC>
	<DOC>NCT02804399</DOC>
	<brief_summary>The purpose of this study is to estimate the effect of rifampin on the single dose PK of PF-06463922.</brief_summary>
	<brief_title>A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers</brief_title>
	<detailed_description>This will be a Phase 1, open-label, 2-period, 2-treatment, fixed-sequence, cross-over study in approximately 12 healthy subjects employing administration of a single oral dose of PF-06463922 in the fasted state alone, and with multiple dosing of rifampin 600 mg once a day to estimate the effect of multiple dose rifampin on the single dose PK of PF-06463922.</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Healthy female subjects of nonchildbearing potential and/or male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs) Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease Any condition possibly affecting drug absorption Positive urine drug screen History of HIV, Hep B or Hep C History of regular alcohol consumption History of cardiac arrhythmia, history of AV block, history of symptomatic bradycardia, history of QTc prolongation History of pancreatitis or hyperlipidemia, elevated lipase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>rifampin</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>PF-06463922</keyword>
	<keyword>drug interaction</keyword>
</DOC>